Current Management of Post-radical Prostatectomy Urinary Incontinence.

detrusor activity incontinence (male) prostate cancer prostatectomy stress incontinence

Journal

Frontiers in surgery
ISSN: 2296-875X
Titre abrégé: Front Surg
Pays: Switzerland
ID NLM: 101645127

Informations de publication

Date de publication:
2021
Historique:
received: 30 12 2020
accepted: 03 03 2021
entrez: 26 4 2021
pubmed: 27 4 2021
medline: 27 4 2021
Statut: epublish

Résumé

Prostate cancer is the second most common cancer in men worldwide. Radical prostatectomy and radiation beam therapy are the most common treatment options for localized prostate cancer and have different associated complications. The etiology of post prostatectomy incontinence is multifactorial. There is evidence in the literature that anatomic support and pelvic innervation are important factors in the etiology of post-prostatectomy incontinence. Among the many surgical and technical factors proposed in the literature, extensive dissection during surgery, damage to the neurovascular bundle and the development of postoperative fibrosis have a substantial negative impact on the continence status of men undergoing RP. Sparing of the bladder neck and anterior, and possibly posterior, fixation of the bladder-urethra anastomosis are associated with better continence rates. Overactive bladder syndrome (OAB) is multifactorial and the exact role of prostate surgery in the development of OAB is still under debate. There are several variables that could contribute to detrusor overactivity. Detrusor overactivity in patients after radical prostatectomy has been mainly attributed to a partial denervation of the bladder during surgery. However, together with bladder denervation, other hypotheses, such as the urethrovesical mechanism, have been described. Although there is conflicting evidence regarding the importance of conservative treatment after post-prostatectomy urinary incontinence, pelvic floor muscle training (PFMT) is still considered as the first treatment choice. Duloxetin, either alone or in combination with PFMT, may hasten recovery of urinary incontinence but is often associated with severe gastrointestinal and central nervous side effects. However, neither PFMT nor duloxetine may cure male stress urinary incontinence. The therapeutic decision and the chosen treatment option must be individualized for each patient according to clinical and social factors. During the recent years, the development of new therapeutic choices such as male sling techniques provided a more acceptable management pathway for less severe forms of urinary incontinence related to radical prostatectomy. Following this perspective, technological improvements and the emergence of new dedicated devices currently create the premises for a continuously positive evolution of clinical outcomes in this particular category of patients.

Identifiants

pubmed: 33898508
doi: 10.3389/fsurg.2021.647656
pmc: PMC8063855
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

647656

Informations de copyright

Copyright © 2021 Rahnama'i, Marcelissen, Geavlete, Tutolo and Hüsch.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

World J Urol. 2015 Sep;33(9):1331-6
pubmed: 25416348
Eur Urol. 2009 Jan;55(1):100-19
pubmed: 18823697
World J Urol. 2017 Jan;35(1):145-151
pubmed: 27156092
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
J Urol. 2008 Jan;179(1):226-31
pubmed: 18001790
Eur Urol. 2007 Jul;52(1):38-45
pubmed: 17403565
BJU Int. 2009 Oct;104(7):991-5
pubmed: 19426191
Eur Urol. 2013 Apr;63(4):606-14
pubmed: 22840353
Oncotarget. 2017 May 9;8(19):32237-32257
pubmed: 27852051
Korean J Urol. 2013 Jan;54(1):15-21
pubmed: 23362442
Eur Urol Focus. 2017 Oct;3(4-5):364-376
pubmed: 29174616
Eur Urol. 2021 Feb 4;:
pubmed: 33551297
Neurourol Urodyn. 2014 Jul;33 Suppl 3:S6-13
pubmed: 25042142
J Urol. 1998 Jan;159(1):100-4; discussion 104-5
pubmed: 9400446
Curr Urol Rep. 2018 Oct 10;19(12):95
pubmed: 30306278
Tunis Med. 2017 Apr;95(4):229-235
pubmed: 29492925
Urology. 2008 Jan;71(1):85-9
pubmed: 18242371
J Urol. 2004 May;171(5):1866-70; discussion 1869-70
pubmed: 15076295
Curr Urol. 2015 May;8(1):43-8
pubmed: 26195963
Urology. 1994 Oct;44(4):530-4
pubmed: 7941191
Eur Urol Focus. 2019 Sep;5(5):823-830
pubmed: 29759661
Neurourol Urodyn. 2016 Jan;35(1):74-80
pubmed: 25327701
Low Urin Tract Symptoms. 2020 Sep;12(3):223-234
pubmed: 32207219
Urol Int. 2017;99(1):14-21
pubmed: 27598774
J Urol. 1999 Jul;162(1):204-12
pubmed: 10379788
World J Urol. 2003 Aug;21(3):167-70
pubmed: 12898170
World J Urol. 2016 Jul;34(7):1025-30
pubmed: 26582060
Urologe A. 2012 Mar;51(3):341-7
pubmed: 22399110
ANZ J Surg. 2021 Apr;91(4):521-529
pubmed: 33319438
Prog Urol. 2012 Jul;22(8):475-81
pubmed: 22732583
Neurourol Urodyn. 2018 Aug;37(6):2008-2014
pubmed: 29635709
Neurourol Urodyn. 2019 Feb;38(2):433-477
pubmed: 30681183
Int J Urol. 2010 Jul;17(7):643-8
pubmed: 20438594
Maturitas. 2009 Aug 20;63(4):323-8
pubmed: 19615834
J Urol. 2018 Jan;199(1):245-250
pubmed: 28823767
Korean J Urol. 2013 Sep;54(9):598-602
pubmed: 24044093
BJU Int. 2017 Jan;119(1):22-29
pubmed: 27444952
Prog Urol. 2017 Mar;27(4):238-243
pubmed: 28043779
Eur Urol Focus. 2020 May 15;6(3):575-592
pubmed: 30718160
Neurourol Urodyn. 2016 Nov;35(8):875-881
pubmed: 26397171
Physiotherapy. 2019 Sep;105(3):338-345
pubmed: 30630622
Eur Urol. 2013 Apr;63(4):681-9
pubmed: 23219375
J Urol. 1974 Jul;112(1):75-80
pubmed: 4600662
Can Urol Assoc J. 2013 Jan-Feb;7(1-2):E33-7
pubmed: 22277630
J Urol. 2009 Jun;181(6):2622-7
pubmed: 19375102
Am J Anat. 1980 Jun;158(2):229-46
pubmed: 7416058
J Urol. 2003 Mar;169(3):1017-9
pubmed: 12576835
J Urol. 2000 Jun;163(6):1761-6
pubmed: 10799177
BJU Int. 2020 Sep 15;:
pubmed: 32929874
Int J Urol. 2008 Oct;15(10):910-4
pubmed: 18761534
World J Urol. 2018 Apr;36(4):609-621
pubmed: 29362896
Eur Urol. 2007 Jun;51(6):1559-64
pubmed: 16942833
Urology. 2013 May;81(5):1034-9
pubmed: 23465151
Urology. 2001 Oct;58(4):570-2
pubmed: 11597541
Eur Urol. 2015 Feb;67(2):273-80
pubmed: 25217421
Neurourol Urodyn. 2002;21(2):167-78
pubmed: 11857671
Adv Ther. 2019 Feb;36(2):426-441
pubmed: 30560525
Cochrane Database Syst Rev. 2015 Jan 20;1:CD001843
pubmed: 25602133
Lancet Oncol. 2018 Aug;19(8):1051-1060
pubmed: 30017351
Eur Urol. 2017 Jun;71(6):936-944
pubmed: 27720536
J Urol. 2000 Jun;163(6):1767-70
pubmed: 10799178
Transl Androl Urol. 2020 Jun;9(3):1099-1107
pubmed: 32676393
Adv Urol. 2016;2016:6054730
pubmed: 27022393
J Urol. 2003 May;169(5):1766-9
pubmed: 12686829
Urology. 2005 Aug;66(2):392-6
pubmed: 16040102
Int J Urol. 2014 Mar;21(3):294-300
pubmed: 24033774
Neurourol Urodyn. 2006;25(1):2-7
pubmed: 16224797
Int Braz J Urol. 2016 May-Jun;42(3):531-9
pubmed: 27286117
Eur Urol. 2015 Aug;68(2):216-25
pubmed: 25770484
Eur Urol. 2007 Sep;52(3):860-6
pubmed: 17316969
BJU Int. 2017 May;119(5):785-792
pubmed: 27868328
Urol Int. 2016;96(2):164-70
pubmed: 26780553
Neurourol Urodyn. 2019 Sep;38(7):1804-1811
pubmed: 31321804
BJU Int. 2017 Apr;119(4):626-630
pubmed: 27862836
Neurourol Urodyn. 2019 Dec;38 Suppl 5:S119-S126
pubmed: 31821626

Auteurs

Mohammad S Rahnama'i (MS)

Urology Department, Uniklinik RWTH Aachen, Aachen, Germany.

Tom Marcelissen (T)

Maastricht University Medical Center (MUMC+), Maastricht, Netherlands.

Bogdan Geavlete (B)

Bucharest University Emergency Hospital, Bucharest, Romania.

Manuela Tutolo (M)

Division of Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.

Tanja Hüsch (T)

Mainz University Hospital, Mainz, Germany.

Classifications MeSH